Impact of endometriosis and its staging on assisted reproduction outcome: systematic review and meta-analysis
M.A.P. Barbosa, D. M. Teixeira, P.A.A.S. Navarro, R.A. Ferriani, C. O. Nastri, W. P. Martins
Volume 44, Issue 3, Date: September 2014, Pages 261-278
http://onlinelibrary.wiley.com/doi/10.1002/uog.13366/abstract
Impact of endometriosis and its staging on assisted reproduction outcome: systematic review and meta-analysis
M.A.P. Barbosa, D. M. Teixeira, P.A.A.S. Navarro, R.A. Ferriani, C. O. Nastri, W. P. Martins
Volume 44, Issue 3, Date: September 2014, Pages 261-278
http://onlinelibrary.wiley.com/doi/10.1002/uog.13366/abstract
Introduction to the WCRF International Continuous Update Project
By Dr Rachel Thompson, Head of Research Interpretation/ Head CUP Secretariat
6 December 2014, UICC World Cancer Congress, Melbourne
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Salina Abdul Aziz. MREC Chairperson
More information, please visit: https://clinupcovid.mailerpage.com/resources/p9f2i7-introduction-to-phase-2-3-trial-s
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Alan Fong Yean Yip, Consultant Cardiologist & CRC head of Sarawak General Hospital and Mr. Chew Chun Keat, Technical Head of Centre for Clinical Trial, ICR
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-cl
Clinical Research Conduct and Management Certificate Information SessionSarah Benzuly-Nardinelli
Learn to master practical aspects of clinical trial conduct and management, including clinical trial phases and design, planning, implementation, and more. Find out how this program can prepare you for a career in the growing field of clinical research.
Professor Martin Wiseman presentation on The Continuous Update Project: Introduction to the Project at FENS European Nutrition Conference, 20-23 October 2015 Berlin (Germany).
The presentation doc used for the Franklin, MA School Committee meeting on Feb 9, 2021 to provide insights on the proposed pool testing pilot for COVID-19
Biomarker is an objective measure that has been evaluated and confirmed either as an indicator of physiologic health, a pathogenic process or a pharmacologic response to a therapeutic intervention. Biomarkers, whether produces by normal healthy individuals or by individuals affected by specific systemic diseases, are tell tale molecules that could be used to monitor health status, disease onset, treatment response and outcome.The biomarkers can help for the determination of present as well as future disease activity along with diagnosis and previous periodontal diseases.
Introduction to the WCRF International Continuous Update Project
By Dr Rachel Thompson, Head of Research Interpretation/ Head CUP Secretariat
6 December 2014, UICC World Cancer Congress, Melbourne
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Salina Abdul Aziz. MREC Chairperson
More information, please visit: https://clinupcovid.mailerpage.com/resources/p9f2i7-introduction-to-phase-2-3-trial-s
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Alan Fong Yean Yip, Consultant Cardiologist & CRC head of Sarawak General Hospital and Mr. Chew Chun Keat, Technical Head of Centre for Clinical Trial, ICR
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-cl
Clinical Research Conduct and Management Certificate Information SessionSarah Benzuly-Nardinelli
Learn to master practical aspects of clinical trial conduct and management, including clinical trial phases and design, planning, implementation, and more. Find out how this program can prepare you for a career in the growing field of clinical research.
Professor Martin Wiseman presentation on The Continuous Update Project: Introduction to the Project at FENS European Nutrition Conference, 20-23 October 2015 Berlin (Germany).
The presentation doc used for the Franklin, MA School Committee meeting on Feb 9, 2021 to provide insights on the proposed pool testing pilot for COVID-19
Biomarker is an objective measure that has been evaluated and confirmed either as an indicator of physiologic health, a pathogenic process or a pharmacologic response to a therapeutic intervention. Biomarkers, whether produces by normal healthy individuals or by individuals affected by specific systemic diseases, are tell tale molecules that could be used to monitor health status, disease onset, treatment response and outcome.The biomarkers can help for the determination of present as well as future disease activity along with diagnosis and previous periodontal diseases.
Traditionally, physicians recruited clinical trial subjects, but pharmaceutical companies have become ever more involved through centralized campaigns. Physicians are vital to a trial and the pharmaceutical effort helps shift some of the recruitment demands away from the site to allow them to focus on the subjects. Thus, it is practical to understand if different recruitment methods could change or skew the study population. This study determines if differences or similarities occurred between subjects recruited by physicians and pharmaceutical companies. It discovered that some of both occurred. The pharmaceutical company efforts helped recruit potential subjects from the general population that were similar to subjects recruited by the physicians, but this particular campaign was limited by language which affected recruitment of Hispanic subjects. The social impact of this study provides insight about pharmaceutical company recruitment. Since the National Library of Medicine has indicated that clinical trials should reflect the broader diseased population, the efforts of the pharmaceutical company can help support the physicians’ efforts by recruiting from the broader population. Together, both efforts can create a global good by allowing the trial to reflect the population of post-approval use. These findings still raise a question about the proper balance between the two recruitment groups so that the intended characteristics of the diseased population are maintained. Because differences between physician and pharmaceutical recruited subjects can exist, the potential of one group to bias the trial results exist. As such, some analysis by recruitment method can help ensure that variations in the study population are minimal without skewing the data to create positive study results.
How evidence affects clinical practice in egyptWafaa Benjamin
Evidence based medicine is the gold standard for clinical care.
It implies the integration of best research evidence with clinical expertise and patient values.
There is still a wide gap between availability of evidence and its incorporation into routine practice in our country.
Barriers to implementation could be personal, social, institutional, financial and legal barriers.
True practice of evidence based care can only occur where evidence based decisions coincide with patients’ beliefs and clinicians’ preferences.
Continuing medical education programs should be set with integrating evidence based medicine teaching and learning within clinical training.
The importance of presence of local national guidelines which need to take into account variation in expertise, resources and patient preferences across our geographical and cultural contexts .
Customisation of a guideline to meet the local needs of a target patient population is critical to successful implementation.
Objective: To evaluate the utility of a targeted lecture in improving FP awareness amongst clinicians.
Design: This is a dual institution, prospective survey-based study assessing if an educational lecture can increase the likelihood of FP consideration, discussion, and referral.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
1. Wendy Johnson
Clinical Research Associate
Education
University of North Carolina at Greensboro
Bachelors of Science
Biology
Pfeiffer University
Masters
Health Administration
Summary
• Over 4 years of experience working in a clinical laboratory and over 8 years of experience as a
medical laboratory technologist.
• Clinical Laboratory Areas include:
Oncology
Fluorescence In-Situ Hybridization (FISH) Assay to detect breast cancer
Epidermal Growth Factor Receptor Immuohistochemical (EGFR IHC) Assay to detect colon
cancer and used in clinical trial studies
Nuclear Matrix Protein 22 ELISA Assay to detect bladder cancer
Clinical Chemistry
Isoelectric Focusing (IEF) and High Performance Liquid Chromatography (HPLC) to detect
abnormal hemoglobin disorders
Electrospray Tandem Mass Spectrometry (MS/MS) to identify abnormal disorders of the
metabolism
Molecular Biology
PCR Amplification on high IRT level patients to detect if Cystic Fibrosis mutations were present
2. Professional Experience
DOCS Global
Clinical Research Associate
January 2016-Current
Design, plan, coordinate, and conduct all activities involved in
initiating, monitoring, and completing clinical research studies for in
vitro diagnostics.
Clinical Research Associate
January 2016-Current Agent representing Roche Diagnostics, Clinical Operations
Responsibilities:
• Performing or coordinating aspects of external clinical
studies including site selection, study initiation, site
monitoring, and study close out.
• Maintaining communication with study investigators to
ensure studies are completed in a timely fashion and
ensuring that study objectives are met.
• Interfacing with other Roche staff to support post launch
activities.
• Ensuring that studies adhere to FDA regulations, Good
Clinical Practices, IVD directives, and Roche policies and
procedures.
North Carolina State
Laboratory of Public Health
Medical Laboratory
Technologist
May 2011 to December 2015
Responsible for performing genetic disorder tests (cross-trained) in
all laboratories of Newborn Screening which include:
Hemoglobinopathies, Cystic Fibrosis, and Tandem Mass
Spectrometry.
Responsibilities:
• Interpreted, analyzed, and reported accurate test results of
patients.
• Provided customer service and educational support to
healthcare providers.
• Developed and implemented activities that were indicators
and monitors of accountability in the quality assurance
program (QA program includes test methodologies,
evaluation of patient test results, personnel competence,
communications, quality assurance records review, quality
control, proficiency testing, and complaint investigations).
Johnson_Wendy_15-Jan-2016 Page 2 of 4
3. • Increased quality improvement of receiving patient samples.
LabCorp, Inc.
Oncology Technologist
January 2008 to May 2011
LabCorp, Inc.
Specimen Laboratory
Accessioner
August 2007- December 2007
Performed various prognostic cancer testing such as lung, colon,
bladder, and primarily breast cancer patients.
Responsibilities:
• Evaluated and documented HER-2/neu signal intensity on
slides with an epifluorescence microscope for patient
records. These results helped pathologists determine
quickly if the patient was applicable for the Herceptin (breast
cancer) drug.
• Help initiated and performed clinical trials from global clients
using the Epidermal Growth Factor Receptor (EGFR)
Immunohistochemical (IHC) assay to detect cancer in the
lung and colon tissue.
Received, sorted, and accessioned blood, urine, and saliva
specimens for occupational testing.
Responsibilities:
• Regularly exceeded department sample processing goals by
working overtime as needed to meet deadlines.
• Updated database with patient information to expedite the
process time.
Johnson_Wendy_15-Jan-2016 Page 3 of 4